

MCKUSICK - NATHAN

Department of Genetic Medicine

A large schizophrenia family with a highly penetrant, rare, nonsynonymous functional variant in the NRXN1 interacting Caskin 1

D. Avramopoulos^{1,} M. Wahbeh¹, A. Hatzimanolis², S. Bacharaki³, S. Dimitrakopoulos², X. Yang¹,

K. Perzel-Mandell¹, R. Wang¹ & N. Stefanis²,

¹Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.; ²Department of Psychiatry, School of Medicine, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece.; ³Department of Psychiatry, General Hospital of Syros, Cyclades, Greece.



National & Kapodistrian University of Athens

Introduction

- A large family with history of psychiatric illness presented with what appears to be an autosomal dominant inheritance pattern with high penetrance (< 100% including 2 obligate carriers).
- DNA is available from individuals with identifying numbers.
- Proband is marked with an arrow.



Variant in CASKIN1 predicted to be damaging

	Variant	pLI	missense Z	Presence in databases	VEST	fathmm	LJB-all	SIFT
RHEBL1	Valine 114→ Leucine	0	0.96	N/A in dbSNP, ExAC, gnomAD	0.6	0.98511	0.56	0.2
CASKIN1	Aspartate 1204 → asparagine	1	2.65	N/A in dbSNP, ExAC, gnomAD	0.025	0.94836	0.77	0.05

• **pLI:** Probability of loss of function intolerance.

- **missense Z:** + Z scores indicate intolerance to variation.
- VEST: Predicts the functional significance of a missense mutation based on the probability that it's pathogenic. Scores near 1 indicate a functional prediction.

CRISPR/Cas9 used to introduce CASKIN1 variant into hiPSCs to asses functionality in isogenic lines

• We introduced 4 bp changes in *CASKIN1*. The Variant and 3 synonymous changes (abolishment of gRNA1 and 2 PAM sites and the first Hha1 restriction site).

216 bp 85 bp 84	bp 37 bp





- Clinical evaluation: MINI International Neuropsychiatric Interview and detailed medical records review.
- Best estimate diagnoses using DSM-IV criteria after a 2 stage consensus diagnosis (SD, SB and NS).

Code	Sex	Age (2016)	Diagnosis (MINI Interview)	DSM IV Diagnosis	
BH8802_12	F	74	Psychotic Disorder	Schizophrenia	
BH8802_13	F	49	Psychotic Disorder	Schizophrenia	
BH8802_14	F	82	Healthy	Healthy	
BH8802_15	Μ	86	Healthy	Healthy	
BH8802_10	F	58	Healthy	Healthy	
BH8802_9	Μ	56	Healthy	Healthy	
BH8802_8	M	55	Psychotic Disorder	Schizophrenia	
BH8802_2	F	50	Psychotic Disorder	Schizophrenia	
BH8802_11	Μ	30	Healthy	Healthy	
BH8802_5	Μ	31	Healthy	Healthy	
BH8802_1	M	30	Mood Disorder with psychotic features	Bipolar Disorder	
BH8802_6	F	27	Psychotic Disorder	Schizoaffective Disorder (bipolar type)	
BH8802_4	М	26	Healthy Healthy		
BH8802_7	Μ	23	Healthy Healthy		

Most distant affected relatives to the proband (marked with red circles) were whole exome sequenced to minimize shared alleles that are only due to relatedness.
Sequencing was done by the Baylor Hopkins Center for Mendelian Genomics.

- SIFT: Predicts an amino acid substitution's affect on protein function.
 Close to 0 scores mean substitution is intolerable.
- fathmm: Predicts the consequences of coding variants. Variant is considered deleterious at scores > 0.5.
- **Hypothesis:** CASKIN1 (Aspartate 1204 \rightarrow asparagine) is the causative SZ highly penetrant variant in this family

Low SZ polygenic risk scores in non-penetrant individuals

- Polygenic Risk Scores (PRS) for all individuals were calculated using the PGC2 GWAS as reference.
- All possible permutations were calculated for this family and this perfect separation can be observed by chance ~21% of the time.
 Albeit weak, this is consistent with polygenic scores being important for the penetrance of other damaging

variants



- Hha1 digestion of bulk cells derived from gRNA1 transfection shows high editing efficiency (lane 1 and 2). Lane 3 is an undigested control.
 Representative gel of Hha1 digestion of single clones. Lane 6 and 9 show positive edited clones. Lane 7 and 10 show unedited clones. Lane 17 is digested bulk as control. Sanger sequencing confirmed the clone in lane 9. Clone in lane 6 was lost due to contamination. More negative clones were picked and confirmed.





Exome sequencing identified 2 variants in genes expressed in brain that pass initial filtering

 Criteria for initial variant filtering: Allele frequency <1% in public data bases.

- Present in a gene expressed in brain.
- 2 variants identified are in the genes RHEBL1 and CASKIN1.
- All available DNA was then sequenced for both variants. Genotypes highlighted in the pedigrees bellow.



CASKIN1 competes with MINT1 for binding CASK, and directly interacts with NRXN1



 The simplified graph shows 2/3 of the proteins involved in tripartite complexes that include CASK, and either MINT1 or CASKIN1 (as the compete for CASK interaction) and their interaction with neurexin at the synapse.

CRISPR/Cas9 used to introduce CASKIN1 variant into hiPSCs to asses functionality in isogenic lines



NGN2 directed induction generates homogeneous populations of glutamatergic neurons





- Simplified differentiation protocol shown above
- TUJ1 and DAPI staining shows that most cells have successfully differentiated into neurons.

Summary and Conclusions

• Screening a family with multiple schizophrenia affected individuals and an apparent autosomal dominant inheritance, we identified 1 variant that perfectly segregates with the disease. The variant is in *CASKIN1* which is expressed in brain and has not been previously observed. It is involved in the neurexin-neuroligin signaling pathway

 This variant was excluded because there is a homozygote and multiple heterozygous individuals who were unaffected.





at the synapse and interacts specifically with CASK and neurexin 1
which had been shown to be involved in schizophrenia development.
We have introduced this variant into hiPSCs. Further follow up for the functionality of this variant is pending.

References

Dachtler, J., Ivorra, J. L., Rowland, T. E., Lever, C., Rodgers, R. J., & Clapcote, S. J. (2015). Heterozygous deletion of α-neurexin I or α-neurexin II results in behaviors relevant to autism and schizophrenia. *Behavioral Neuroscience*, *129*(6), 765–776
Grayton, H. M., Missler, M., Collier, D. A., & Fernandes, C. (2013). Altered Social Behaviours in Neurexin 1α Knockout Mice Resemble Core Symptoms in Neurodevelopmental Disorders. *PLoS ONE*, *8*(6).
Kirov, G., Rujescu, D., Ingason, A., Collier, D. A., Odonovan, M. C., & Owen, M. J. (2009). Neurexin 1 (NRXN1) Deletions in Schizophrenia. *Schizophrenia Bulletin*, *35*(5), 851–854.
Stafford, R. L., Ear, J., Knight, M. J., & Bowie, J. U. (2011). The Molecular Basis of the Caskin1 and Mint1 Interaction with CASK. *Journal of Molecular Biology*, *412*(1), 3–13.
Tabuchi, K., Biederer, T., Butz, S., & Südhof, T. C. (2002). CASK Participates in Alternative Tripartite Complexes in which Mint 1 Competes for Binding with Caskin 1, a Novel CASK-Binding Protein. *The Journal of Neuroscience*, *22*(11), 4264–4273. **Acknowledgement**: We thank Dr. Debamitra Das for help with differentiations and the Baylor Hopkins Center for Mendelian Genomics for whole exome sequencing.